Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus‐infected patients: Long‐term follow‐up results from the open‐label, Phase II IMPACT study

BACKGROUND AND AIMS: Direct‐acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult‐to‐cure/cirrhotic patients typically require a longer treatment duration and les...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawitz, Eric, Poordad, Fred, Gutierrez, Julio A., Beumont, Maria, Beets, Greet, Vandevoorde, Ann, Remoortere, Pieter Van, Luo, Donghan, Vijgen, Leen, Eygen, Veerle Van, Gamil, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136481/
https://www.ncbi.nlm.nih.gov/pubmed/32270053
http://dx.doi.org/10.1002/hsr2.145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136481/
https://www.ncbi.nlm.nih.gov/pubmed/32270053
http://dx.doi.org/10.1002/hsr2.145

Ejemplares similares